Carmell Therapeutics Corp...

0.20
0.01 (2.77%)
At close: Mar 07, 2025, 3:55 PM

Company Description

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging.

Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing.

The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Carmell Therapeutics Corporation
Carmell Therapeutics Corporation logo
Country United States
IPO Date Sep 23, 2021
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Rajiv Sarman Shukla

Contact Details

Address:
2403 Sidney Street
Pittsburgh, Pennsylvania
United States
Website https://www.carmellrx.com

Stock Details

Ticker Symbol CTCX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001842939
CUSIP Number 142922103
ISIN Number US1429221039
Employer ID 00-0000000
SIC Code 6770

Key Executives

Name Position
Rajiv Sarman Shukla Chief Executive Officer & Executive Chairman
Bryan J. Cassaday Chief Financial Officer
Dr. James Burgess M.D. Founder
Dr. Lee Weiss Ph.D. Founder
Dr. Phil Campbell Ph.D. Founder and Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 10, 2025 424B3 Filing
Mar 10, 2025 8-K Current Report
Mar 06, 2025 424B3 Filing
Mar 05, 2025 8-K Current Report
Feb 13, 2025 424B3 Filing
Feb 10, 2025 DEF 14A Filing
Feb 10, 2025 DEF 14A Filing
Feb 07, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 03, 2025 S-3 Filing
Jan 31, 2025 PRE 14A Filing